While lithium salts arc efficacious in manic states 20% are nonresponders. Amongst various therapeutic advances which have occurej, carbamazepine seems promising (Pou, 1982) . Further, when used in combination, carbamazepine and lithium seem to function synergistically (Lipinski & Pope, 1982) . VVc had an opportunity to tty this combination, in a manic patient who responded inadequately to lithium carbonate.
CASE REPORT
Ms. J, an 18 yrs. old female patient with a family history of affective illness was admitted in August 1982 with clinical piciuie of acute manic excitement, with history of three manic epi-odes earlier between 197C and 1980. She was treated with Haloperidol (15 mgs/day) and lithium carbonate (1200 mgs/day) orally and was discharged 2 weeks later following clinical improvement. However, she was readmitted within 3 weeks in September, 1932 with a relapse in her clinical condition, though the family claimed full thug compliance. With Haloperidol (20 mgs/day) and lithium carbonate (1200 mgs/day) she had to be given 4 modified bilateral EGTs. She showed clinical improvement and was discharged six weeks later.
Within 3 weeks again, the patient had to be readmitted in acute manic excitement. Serum lithium estimation was carried out to ascertain the drug compliance which indicated that the compliance had been adequate. After admission, the patient showed no improvement with chlorpromazine (600 mgs/ day) and lithium carbonate (1509 mgs/ day).
Since the patient had iiot responded adequately to lithium carbonate as evidenced by rapid relapses and the persistent manic feitures despite adequate serum levels (between 0.7 to 1.4 mEq/L) foi sufficient length of time (14 weeks) alternative management was consideied and all the drugs were stopped. She was started on carbamazepine 600 mgs/ day orally in divided doses. After one week, the clinical features remained static. Lithium carbonate (1500 mgs/day) was reintroduced along with carbamazepine (600 mgs/day). Within one week, marked clinical improvement was evident and the patient has been on regular follow-up as an out-patient.
For 3 months she has not relapsed and main- tains complc.e recovery on lithium carbonate (1500 mgs/day) and Carbamazepine (400 mgs/day;.
COMMENT
Our patient was treated with Lithium Carbonate and neuroleptics during the first two admissions. The improvement on each occassion occurcd after a long interval; 3 weeks on the first occassion and 6 weeks during the second admission, during which EGTs became necessary to obtain better results. Afier discharge, the improvement was sustained for a very short period (3 weeks) on bo'h the occasions deipite regular medication. During the second admission the patient had developed severe drug induced extrapyramidal side-effects restricting the use of neuroleptics in high do.es. During the third admission, while the patient did not show any response to carbamazepine alone, with a combination of carbamazepine and lithium she showed marked improvemen* within ore week. This improvement has been well maintained over a period of next 3 months. Thus, it suppo.ts the earlier report (Lipir.ski & Pope, 1982 ) of a possible synergistic action for this efficacy. Because a single c isc doe^ not fully substantiate the routine clinical use of this combination when needed, we are at pre ent evaluating the efficacy of this combination in a clinical crossover trial.
